Bacterial Vaginosis In Adult Women Therapeutics
1. Solosec patent expiration
Treatment: Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older; Treatment of Read More
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12280037 | EVOFEM INC | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Dec, 2041
(15 years from now) | |
| US10335390 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11602522 | EVOFEM INC | Secnidazole for use in the treatment of sexually transmitted infection |
Sep, 2035
(9 years from now) | |
| US10849884 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US10857133 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11000508 | EVOFEM INC | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(9 years from now) | |
| US11000507 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11020377 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US10682338 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11684607 | EVOFEM INC | Secnidazole for use in the treatment of bacterial vaginosis |
Sep, 2035
(9 years from now) | |
| US11324721 | EVOFEM INC | Secnidazole for use in the treatment of trichomoniasis |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 15, 2022 |
| New Indication(I-866) | Jun 30, 2024 |
| New Patient Population(NPP) | Jan 26, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 15, 2027 |
Drugs and Companies using SECNIDAZOLE ingredient
NCE-1 date: 15 September, 2026
Market Authorisation Date: 15 September, 2017
Dosage: GRANULE
More Information on Dosage
SOLOSEC family patents
